Ionis Pharmaceuticals IONS Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's additional paid-in capital?
- Ionis Pharmaceuticals (IONS) reported additional paid-in capital of $3.25B in Q1 2026.
- How has Ionis Pharmaceuticals's additional paid-in capital changed year-over-year?
- Ionis Pharmaceuticals's additional paid-in capital increased by 11.9% year-over-year, from $2.9B to $3.25B.
- What is the long-term trend for Ionis Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's additional paid-in capital has grown at a 10.7% compound annual growth rate (CAGR), from $1.9B to $3.15B.
- What does additional paid-in capital mean?
- The total amount of money investors paid for shares above their nominal par value.
- How do you interpret additional paid-in capital?
- An increase indicates successful equity issuance or exercise of stock options, while a decrease is rare and usually relates to share buybacks or capital restructuring.
- How does additional paid-in capital compare across companies?
- Standard across all public companies; reflects historical dilution and financing strategy.